Novo Nordisk Responds to Rival Launch with Clinical Data and Subscription Model

Novo Nordisk releases head-to-head data favoring oral Wegovy over Foundayo and launches a direct-to-consumer subscription plan to retain patients amid intense GLP-1 competition.

Novo Nordisk has moved swiftly to counter the recent U.S. launch of Eli Lilly's oral weight-loss drug, Foundayo. On the very same day its competitor entered the market, the Danish pharmaceutical giant released comparative analysis favoring its own oral Wegovy pill and introduced a new subscription pricing plan aimed at retaining patients who pay out-of-pocket.

Subscription Program Targets Patient Retention

A key commercial initiative launched alongside the data is a direct-to-consumer subscription program for patients without insurance coverage. Available through telehealth partners including Ro, WeightWatchers, and LifeMD, the program offers three-, six-, and twelve-month plans for the Wegovy injection or the two highest doses of the oral pill.

The annual subscription for the injection is priced at $249 per month, which can lead to annual savings of up to $1,200 compared to the standard list price. Savings for the oral medication can reach up to $600 per year. This strategy addresses a critical market dynamic: a recent survey indicated that nearly seven out of ten Americans taking a GLP-1 medication said cost influenced their decision to continue treatment. Ensuring long-term adherence is vital for both patient outcomes and sustained revenue.

Head-to-Head Data Favors Oral Wegovy

The comparative data, drawn from the ORION study and previously published trials, shows oral semaglutid (25 mg) achieved an average weight loss of 16.6%. This compares to a 12.4% reduction for Lilly's 36 mg Orforglipron (Foundayo)—a difference of 3.2 percentage points.

The disparity in tolerability appears more pronounced. Patients discontinued Foundayo treatment due to side effects approximately 14 times more frequently than those on the Wegovy pill. Furthermore, in a patient survey, 84% preferred the clinical profile of Novo Nordisk's oral therapy. The complete dataset is scheduled for presentation on April 10 at the Obesity Medicine Association's annual meeting in San Diego.

Despite this favorable data, analysts note a structural disadvantage for Novo's pill: it must be taken in the morning on an empty stomach with a small sip of water, followed by at least 30 minutes of fasting, while Foundayo has no such restrictions. Some market observers, like those at Barclays, report initial signs of "patient warehousing," where physicians may delay new Wegovy prescriptions to first assess Foundayo's real-world performance.

Structural Headwinds and Future Catalysts

These tactical moves occur against a backdrop of significant macroeconomic challenges for Novo Nordisk. The company's adjusted sales growth forecast for 2026, at constant exchange rates, stands at minus 5% to minus 13%. This pressure stems from lower prices due to the U.S. "Most Favored Nations" agreement and the patent expiry for semaglutide in certain markets.

In India, for instance, Novo reduced prices for Ozempic and Wegovy by up to 36% and 48%, respectively, after the semaglutide patent expired on March 20. At least six Indian manufacturers, including Dr. Reddy's, Zydus, and Sun Pharma, have since launched generic versions, some priced up to 70% lower than Novo's products. In the crucial U.S. market, Eli Lilly already commands over 60% of the weight-loss drug market by volume share.

The next significant potential catalyst for Novo Nordisk is the FDA decision on CagriSema, a combination of cagrilintide and semaglutide submitted for obesity treatment. A ruling is expected around the turn of the year 2026/2027, shortly after the company's Capital Markets Day in September 2026. For now, the oral Wegovy pill has reached more than 600,000 patients since its U.S. launch at the start of the year. The coming weeks will reveal whether the combination of compelling ORION data and a strategic subscription model is sufficient to maintain this momentum against the new competitive threat.